Organic Active Ingredients TRIZ Cases

Combines purified DHM, milk thistle extract, and PQQ in oral forms to mitigate hangover symptoms and alcohol-related liver damage.

Pain-focused arthritis treatments may not prevent cartilage breakdown; combining a selective H1 antagonist with anti-inflammatory agents targets both problems.

Functional-group changes tune ACSL5 inhibition to improve insulin sensitivity and address fatty-acid dysregulation in disease.

Quercetin, vitamins, zafirlukast, and optional folic acid combine to address inflammation and cellular damage in cancer and neurological disease.

Drug-resistant CML clones challenge current inhibitors, while tailored substituents and linkages support inhibition of mutant BCR-ABL1.

GalNAc-conjugated RNAi targets PCSK9 mRNA in hepatocytes, supporting extended dosing intervals for hypercholesterolemia treatment.

N-glycosylation inhibitors such as ManN stimulate endothelial proliferation and angiogenesis to improve brain blood flow after ischemic stroke.

Specific substitutions and linkages tune TYK2 inhibitors to limit JAK2 off-target inhibition while treating TYK2-mediated disorders.

Gallic acid esters such as ethyl gallate improve SAM-e uptake and plasma levels in composite formulations, supporting less frequent dosing.

Existing vericiguat routes use many steps; a fluorinated nitroso pyrimidine intermediate enables shorter, higher-yield synthesis.

KCC2 inhibitors such as furosemide regulate neuronal chloride, normalize GABAergic signaling, and improve memory performance in older adults.

Measuring SQSTM1/p62 in tumor samples helps predict checkpoint immunotherapy sensitivity or resistance before treatment, supporting tailored therapy.

Pectin polysaccharides administered intravenously bind SARS-CoV-2, reducing viral load and infectivity while increasing IgG antibody titers.

This case addresses hormone-therapy risks with a RAR-alpha antagonist that suppresses sperm production and preserves testosterone levels.

This case uses 8- and 6-substituted pyridopyrimidines to bind KRAS G12C cysteine covalently, improving targeted inhibition.

Skin barrier resistance limits topical siRNA delivery, so dissolvable microneedles carry targeted nanoplexes to cells for gene silencing.

A chevron-sculptured chitosan film protects the prostatic neurovascular bundle while supporting nerve regeneration after prostatectomy.

Linked resistance-breaker and antibiotic moieties raise intracellular drug levels while reducing reliance on toxic high-dose inhibitors.

This case develops benzofurans, benzothiophenes, and indoles as small molecules for direct intracellular tau oligomer inhibition.

Rosiglitazone combinations inhibit osteoblasts to prevent abnormal bone growth.

This case uses aminoalkyl esters of monomethyl fumarate to improve stability, absorption, and therapeutic coverage for 8 to 24 hours.

A fish-gelatin, fast-dispersing rimegepant formulation supports rapid dissolution and improved efficacy for migraine treatment.

This case develops soluble, short-acting S-alaninate compounds for dual factor Xa and thrombin inhibition in acute anticoagulation.

This case uses 25 mg tegoprazan to maintain symptom-free and erosion-free states during long-term GERD recurrence prevention.

Tri-substituted imidazoles inhibit TGF-β signaling while addressing formulation limits.

This case uses structure-tuned tetrahydroisoquinolines to inhibit PRMT5 selectively for cancer and hemoglobinopathy research.

This case uses 1-piperidinpropionic acid to suppress SerpinB3, reduce resistance, and restore chemotherapy response in tumors.

This case addresses limited dual-receptor coverage with an aliphatic acid amide compound for neuropsychiatric treatment.

This case uses substituted tetrahydroisoquinoline compounds to activate GPR120 and address metabolic and inflammation-related disorders.

Polymer carriers stabilize the amorphous dispersion, improving solubility and release against resistant anaerobes.

This case combines pyrazolo[3,4-d]pyrimidine compounds with antitumor agents to enhance efficacy while limiting off-target kinase effects.

This case uses pressure cooking above 121°C to extract proteins, amino acids, chondroitin sulfate, and polyphenols from poultry broth.

This case uses Compound (I) to inhibit HCK and mutated BTK, addressing BTK inhibitor resistance in Waldenström's Macroglobulinemia.

A buffered liquid anti-Nectin-4 ADC formulation limits protein aggregation and drug shedding during long-term storage.

This case balances micronized ezetimibe with defined particle-size ranges to achieve 90% release within 30 minutes.

AAV minigenes deliver functional CEP290 fragments to support photoreceptors while avoiding oversized cargo and genome editing.

This case uses controlled water-alcohol ratios and Schüssler salts to extract plant meristem bioactives with improved bioavailability.

This case repurposes waste lignin through sulfation for pathogen adsorption, hydrogels, water purification, and antimicrobial coatings.

This case combines sub-500 cP viscosity with up to 45% cannabinoid content and a 4–8 W heater for higher mass per puff.

This case varies C17 triterpenoid polar groups to broaden biological activity across antioxidant and inflammation-related disease targets.

Piperidine diones modulate cereblon to treat AR-mediated disease while reducing toxicity and side effects versus conventional therapies.

Serological markers guide secukinumab dosing for high-risk arthritis patients, targeting IL-17A while addressing response and safety limits.

This case uses liver-specific uptake and molecular tuning to deliver CDK9 inhibitors while limiting peripheral exposure.

This case tunes N-methyl-2-pyridone structures for selective BDII inhibition, solubility, stability, and lower skin toxicity.

This case uses PLA and controlled pore size to limit burst or delayed release while avoiding surgical removal.

A pump spray combines hormone delivery with a washable skin film that limits estradiol and testosterone transfer to others.

This case combines purified CBD with fenfluramine to reduce seizures and help prevent 5-HT2B-related heart valve disease.

A wearable cartridge delivers neutral, isotonic furosemide subcutaneously in 0.5–2 hours, reducing pain and administration complexity.

Starch-polyurethane hydrogels absorb exudate while supporting moist wound healing.

Controlled crystallization produces Forms I–III with lower hygroscopicity and more predictable solubility, stability, and bioavailability.